Benign Prostatic Hyperplasia Treatment Market: Growth Potential and Outlook
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Benign Prostatic Hyperplasia Treatment Market In 2026, And How Will Its Value Evolve By 2030?
The benign prostatic hyperplasia treatment market has witnessed substantial expansion in recent years. This market is projected to expand from $8.69 billion in 2025 to $9.17 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this historic growth include an expanding aging male population, an increase in urinary disorders, the proliferation of urology specialty services, an enhanced adoption of pharmacological treatments, and better availability of diagnostic screening.
The benign prostatic hyperplasia treatment market is projected to experience substantial expansion in the coming years. This market is set to reach $11.29 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this growth during the forecast period include the increasing adoption of robotic-assisted prostate procedures, a growing emphasis on personalized treatment planning, the broadening of home-based therapy options, the expanding integration of digital tools for patient monitoring, and the rising demand for minimally invasive interventions. Key trends anticipated for this period encompass the increasing uptake of minimally invasive surgical techniques, a heightened demand for targeted drug therapies, the expanding utilization of combination treatment strategies, the proliferation of outpatient treatment settings, and an intensified focus on managing symptoms and improving quality of life.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Drivers Are Fueling The Growth Of The Benign Prostatic Hyperplasia Treatment Market?
The increasing acceptance of minimally invasive surgeries is anticipated to drive the growth of the benign prostatic hyperplasia treatment market. These procedures involve minimal or no incisions, employing specialized instruments to shorten recovery durations, alleviate pain, and reduce the risk of complications. The surge in the adoption of minimally invasive surgeries is prompted by benefits such as quicker recovery periods, lessened pain, a decreased likelihood of complications, and improved aesthetic results. When applied to benign prostatic hyperplasia treatment, minimally invasive surgeries offer patients reduced recovery times, lower risks of complications, and effective symptom relief, leading to better overall surgical outcomes. For instance, in September 2023, data from the American Society of Plastic Surgeons (ASPS), a professional association located in the U.S., indicated nearly 25.4 million minimally invasive cosmetic procedures were performed in 2023, representing a 7% increase from 23.7 million in 2022. Therefore, the expanding adoption of minimally invasive surgeries is a key factor propelling the benign prostatic hyperplasia treatment market forward.
Which Segments Define The Benign Prostatic Hyperplasia Treatment Market Segment Structure?
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
What Trends Are Influencing The Benign Prostatic Hyperplasia Treatment Market?
Leading companies in the benign prostatic hyperplasia treatment market are concentrating on creating inventive solutions, such as intraprostatic drug elution therapy, to secure a competitive edge. Intraprostatic drug elution therapy involves implanting a bioabsorbable device directly into the prostate for the sustained, local delivery of a therapeutic agent. For example, in May 2025, Resurge Therapeutics, a US-based urology technology developer, launched a paclitaxel-eluting bioabsorbable implant for BPH; it allows for office-based application, precise drug release, and minor post-procedure discomfort. This localized approach minimizes systemic exposure, improves effectiveness, and helps maintain sexual function. However, its long-term safety and widespread implementation are still undergoing evaluation.
Who Are The Established Players Within The Benign Prostatic Hyperplasia Treatment Market?
Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.
Get The Full Benign Prostatic Hyperplasia Treatment Market Report:
Which Region Leads The Benign Prostatic Hyperplasia Treatment Market In Overall Market Size?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Benign Prostatic Hyperplasia Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia Treatment Market 2026, By The Business Research Company
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Drugs For Benign Prostatic Hypertrophy Market Report 2026
Prostate Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
